Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up.

Autor: Arcieri ES; Department of Ophthalmology, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil; Department of Ophthalmology, Presidente Antônio Carlos University (UNIPAC), Araguari, Minas Gerais, Brazil; Department of Ophthalmology, Federal University of Uberlândia (UFU), Uberlândia, Minas Gerais, Brazil., Paula JS, Jorge R, Barella KA, Arcieri RS, Secches DJ, Costa VP
Jazyk: angličtina
Zdroj: Acta ophthalmologica [Acta Ophthalmol] 2015 Feb; Vol. 93 (1), pp. e1-6. Date of Electronic Publication: 2014 Jul 02.
DOI: 10.1111/aos.12493
Abstrakt: Purpose: To evaluate the efficacy and safety of intravitreal bevacizumab (IVB) in eyes with neovascular glaucoma (NVG) undergoing Ahmed glaucoma valve (AGV) implantation.
Methods: This was a multicentre, prospective, randomized clinical trial that enrolled 40 patients with uncontrolled neovascular glaucoma that had undergone panretinal photocoagulation and required glaucoma drainage device implantation. Patients were randomized to receive IVB (1.25 mg) or not during Ahmed valve implant surgery. Injections were administered intra-operatively, and 4 and 8 weeks after surgery.
Results: After a mean follow-up of 2.25 ± 0.67 years (range 1.5-3 years), both groups showed a significant decrease in IOP (p < 0.05). There was no difference in IOP between groups except at the 18-month interval, when IOP in IVB group was significantly lower (14.57 ± 1.72 mmHg vs. 18.37 ± 1.06 mmHg - p = 0.0002). There was no difference in survival success rates between groups. At 24 months, there was a trend to patients treated with IVB using less antiglaucoma medications than the control group (p = 0.0648). Complete regression of rubeosis iridis was significantly more frequent in the IVB group (80%) than in the control group (25%) (p = 0.0015).
Conclusions: Intravitreal bevacizumab may lead to regression of new vessels both in the iris and in the anterior chamber angle in patients with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. There is a trend to slightly lower IOPs and number of medications with IVB use during AGV implantation for neovascular glaucoma.
(© 2014 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje